Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Arcus Biosciences ( (RCUS) ) just unveiled an update.
Arcus Biosciences, Inc. reported that on March 17, 2026, Chief Operating Officer Jennifer Jarrett notified the company of her decision to resign, with her departure effective March 30, 2026, and the move was not related to any disagreement over operations, policies, or practices. Under a separation agreement, Jarrett will provide periodic advisory services through June 30, 2026, in exchange for an extended 12‑month post‑termination option exercise period for her vested options and a standard release of claims, signaling an orderly leadership transition with ongoing access to her expertise.
The most recent analyst rating on (RCUS) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Arcus Biosciences stock, see the RCUS Stock Forecast page.
Spark’s Take on RCUS Stock
According to Spark, TipRanks’ AI Analyst, RCUS is a Neutral.
The score is held back primarily by weak financial performance driven by large losses and heavy cash burn. Offsetting this, the earnings call pointed to strong clinical progress and a sizeable cash runway, while technicals show an improved price trend but mixed momentum; valuation is constrained by negative earnings and no dividend support.
To see Spark’s full report on RCUS stock, click here.
More about Arcus Biosciences
Arcus Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies. The company operates in the life sciences industry, concentrating on advancing drug candidates and related programs aimed at addressing significant unmet medical needs in its target markets.
Average Trading Volume: 1,268,632
Technical Sentiment Signal: Buy
Current Market Cap: $2.71B
See more insights into RCUS stock on TipRanks’ Stock Analysis page.